Gilead Sciences vs Neurocrine Biosciences (GILD vs NBIX)
Side by side from their SEC filings: revenue, margins, growth, returns and valuation, plus short interest, insider activity and institutional ownership.
Gilead Sciences is the larger company by revenue ($29.4B vs $2.9B) and market value ($161.2B vs $17.3B). Neurocrine Biosciences has grown revenue faster over the last 4 fiscal years (+152.4% cumulative vs +7.8%). Gilead Sciences runs the higher operating margin (34.0% vs 21.6%). Gilead Sciences trades at the lower trailing P/E (17.7x vs 26.8x).
About Gilead Sciences
Gilead Sciences, Inc. is a biopharmaceutical company that develops and markets medicines to treat life-threatening diseases such as HIV, viral hepatitis, COVID-19, and cancer. Its product portfolio includes oral antiretroviral therapies for HIV, treatments for liver diseases like hepatitis B and C, oncology therapies including CAR T-cell treatments, and antifungal and antiviral drugs. The company serves healthcare providers and patients worldwide through its commercial operations in over 35 countries.
About Neurocrine Biosciences
Neurocrine Biosciences Inc is a biopharmaceutical company focused on developing and commercializing treatments for neurological, psychiatric, endocrine, and immunological disorders. Its main products include FDA-approved drugs such as INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease, and CRENESSITY for classic congenital adrenal hyperplasia. The company serves patients in the United States and select international markets through specialty pharmacy networks and a specialized sales force.
Head to head (GILD FY2025 vs NBIX FY2025)
| Metric | GILDFY2025 | NBIXFY2025 |
|---|---|---|
| Revenue | $29.44B | $2.86B |
| Revenue growth (YoY) | 2.4% | 21.4% |
| Gross margin | 78.8% | — |
| Operating margin | 34.0% | 21.6% |
| Net margin | 28.9% | 16.7% |
| Net income | $8.51B | $478.6M |
| Diluted EPS | $6.78 | $4.67 |
| FCF margin | 32.1% | 26.2% |
| ROE | 37.6% | 14.7% |
| Debt / equity | 1.0× | — |
| Market cap | $161.19B | $17.30B |
| P/E (TTM) | 17.7× | 26.8× |
Fundamentals are from each company’s SEC filings (GILD FY2025, NBIX FY2025). P/E and market cap are derived from recent market prices and update daily.
Five-year trend (as reported)
| Revenue | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| GILD | $27.30B | $27.28B | $27.12B | $28.75B | $29.44B |
| NBIX | $1.13B | $1.49B | $1.89B | $2.36B | $2.86B |
Peer standing
Where each company ranks among the 71 biotech companies, on the same scale. Each figure is ranked only against peers that report it. Percentiles describe position in the distribution, not a rating.
| Metric | GILD | NBIX |
|---|---|---|
| Operating margin | 34.0%80th percentile of 31 | 21.6%63rd percentile of 31 |
| Net margin | 28.9%81st percentile of 32 | 16.7%61st percentile of 32 |
| FCF margin | 32.1%81st percentile of 28 | 26.2%78th percentile of 28 |
| Revenue growth (YoY) | +2.4%33rd percentile of 64 | +21.4%54th percentile of 64 |
| ROE | 37.6%92nd percentile of 61 | 14.7%80th percentile of 61 |
| P/E (TTM) | 17.7×50th percentile of 21 | 26.8×75th percentile of 21 |
| Short interest (days to cover) | 2.66d23rd percentile of 71 | 4.20d46th percentile of 71 |
Short interest
| FINRA settlement data | GILD | NBIX |
|---|---|---|
| Shares sold short | 25.5M | 5.5M |
| Change vs prior settlement | +6.8% | -2.8% |
| Days to cover | 2.66 | 4.20 |
| As of settlement | 2026-06-30 | 2026-06-30 |
Source: FINRA Consolidated Short Interest. FINRA is the owner and source of the FINRA-supplied data; republishing or redistributing it is not permitted. Not presented as a percentage of float. No FINRA endorsement of this product is implied.
Insider activity (last 90 days)
| Form 4 open-market activity | GILD | NBIX |
|---|---|---|
| Buys | 0 | 0 |
| Sells | 18 ($10.8M) | 26 ($62.2M) |
Open-market purchases and sales reported on SEC Form 4 (grants, exercises and tax withholding excluded). For context, about 16% of covered companies saw any open-market insider buy in a 90-day window.
Held by the same investors
9 tracked 13F managers hold both Gilead Sciences and Neurocrine Biosciences as of their latest quarterly filings: AQR Capital Management, Bridgewater Associates, Citadel Advisors, D. E. Shaw, Dodge & Cox, Gotham Asset Management, Millennium Management, Renaissance Technologies, Two Sigma Investments. See which superinvestors hold your own portfolio with the smart money checker.
Go deeper
AMGN vs GILDBIIB vs GILDEXEL vs GILDGILD vs MRNAGILD vs RVMDGILD vs TECHAll biotech stocks →All comparisons →
Track GILD and NBIX
Get an alert when either company files something material, see which superinvestors own them, and ask their filings a question with cited answers.
Start monitoring freeIncludes one free filing-grounded research answer. Or check your whole portfolio, no account needed.
Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filings before relying on them. Comparisons are descriptive (higher or lower on a reported figure), not a rating or a recommendation. Informational only. Not investment advice.